Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful conscientiously but unsuccessfully to produce an one off therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the past few shares of mine. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire interview which I came away with a poor impression of the company.

Irony of irony, my bad opinion of the business enterprise has grown steadily, though the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back throughout 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this expertise as well as associated intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 huge number of) plus the first new drug application endorsement ($five million), and also royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous indications and numerous therapies, it’s this individual therapy in addition to a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a likely advantageous therapy in dozens of indications.

Its opening banner on its website (below) shows an energetic company with diverse interests albeit centered on leronlimab, several disease sorts, multiple publications in addition to multiple delivering presentations.

Can it all be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very beginning of the interest of mine in this organization. Judging by way of the multiples of a huge number of various remarks on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this question.

CytoDyn is a classic battleground, or some might say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *